IL-1A

The agreement is based on a jointly owned US patent application that claims methods of assessing a person's risk for generalized osteoarthritis based on IL-1 genotypes.

This article has been updated from an earlier version with additional comments from Eliot Lurier.
By Turna Ray

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.